Acquired Company
Supernus Pharmaceuticals completed the acquisition of Adamas Pharmaceuticals on 11/24/2021 for $8.10 per share in cash plus two non-transferable contingent value rights, with Adamas surviving as a wholly-owned subsidiary.
Adamas Pharmaceuticals Inc. delivers innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. The company is a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. Show more
1900 Powell St Ste 1000, California, 94608-1839, US
Start AI Chat
Market Cap
0.00
52 Wk Range
$N/A - $N/A
Previous Close
$8.22
Open
$8.22
Volume
N/A
Day Range
$8.22 - $8.22
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
0.00%
Institutional Own.
0.00%
Qtr Updated
12/31/24
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|